A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
Public ClinicalTrials.gov record NCT06356311. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician's Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will compare how safe and effective sacituzumab tirumotecan is versus the treatment of physician's choice (TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumotecan is superior to TPC with respect to Overall Survival (OS).
Study identification
- NCT ID
- NCT06356311
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 450 participants
Conditions and interventions
Conditions
Interventions
- Sacituzumab tirumotecan Biological
- Trifluridine-Tipiracil Drug
- Irinotecan Drug
- Paclitaxel Drug
- Docetaxel Drug
- Rescue medications Drug
- Supportive care measures Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 3, 2024 (Actual)
- Primary completion
- Jan 4, 2027 (Estimated)
- Completion
- May 6, 2027 (Estimated)
- Last update posted
- Feb 27, 2026
2024 – 2027
United States locations
- U.S. sites
- 17
- U.S. states
- 15
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner MD Anderson Cancer Center ( Site 0119) | Gilbert | Arizona | 85234 | — |
| UCLA Hematology/Oncology - Santa Monica ( Site 0140) | Los Angeles | California | 90404 | — |
| AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 0129) | Orlando | Florida | 32804 | — |
| Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0108) | Marietta | Georgia | 30060 | — |
| University of Chicago Medical Center ( Site 0120) | Chicago | Illinois | 60637 | — |
| University of Kentucky Chandler Medical Center-Medical Oncology ( Site 0124) | Lexington | Kentucky | 40536 | — |
| The University of Louisville, James Graham Brown Cancer Center-James Graham Brown Cancer Center ( Site 0113) | Louisville | Kentucky | 40202 | — |
| Norton Audubon Hospital-Norton Cancer Institute - Audubon ( Site 0105) | Louisville | Kentucky | 40217 | — |
| Henry Ford Hospital ( Site 0107) | Detroit | Michigan | 48202 | — |
| Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0138) | Fargo | North Dakota | 58122 | — |
| Oregon Health and Science University ( Site 0104) | Portland | Oregon | 97239 | — |
| UPMC Hillman Cancer Center ( Site 0126) | Pittsburgh | Pennsylvania | 15232 | — |
| MUSC Hollings Cancer Center-Hematology Oncology ( Site 0122) | Charleston | South Carolina | 29425 | — |
| Sanford Cancer Center ( Site 0136) | Sioux Falls | South Dakota | 57104 | — |
| The West Clinic, PLLC dba West Cancer Center ( Site 0110) | Germantown | Tennessee | 38138 | — |
| Inova Schar Cancer ( Site 0106) | Fairfax | Virginia | 22031 | — |
| Fred Hutchinson Cancer Center ( Site 0111) | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 151 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06356311, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 27, 2026 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06356311 live on ClinicalTrials.gov.